Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Financings Routine −

Revive Therapeutics Announces Proposed Private Placement

Cash-burning micro-cap biotech raises survival capital via dilutive private placement while pursuing repurposed drug for nerve agents and infectious diseases.

By The Northwire Desk — AI Analysis Jun 26, 2026 · 16:15 RVV · 0.03 Revive Therapeutics Ltd.
Executive Summary
  • Revive Therapeutics announced a proposed private placement of up to 31,250,000 units at $0.032 per unit.
  • Gross proceeds are targeted at approximately $1,000,000.
  • Each unit comprises one common share and one common share purchase warrant exercisable at $0.05 per share for 36 months.
  • Proceeds will be used for working capital.
  • The transaction may close in tranches, subject to customary conditions, with a 4-month and 1-day hold period for investors.
  • Finder compensation is set at 8.0% cash plus 8.0% in warrants with identical terms.
Material Impact
  • The company is in a severe liquidity crisis, with a going concern warning, negative equity of -$4.0M, and only ~$12,665 to $22,665 in cash.
  • The $1M raise is strictly a survival mechanism. It covers a fraction of the $4.15M working capital deficiency and provides roughly 6 months of runway based on a ~$0.17M monthly burn rate.
  • Dilution is immediate and significant: ~7.2% from the share issuance, plus additional dilution from the warrants and finder warrants.
  • The placement price of $0.032 is at a slight premium to the recent $0.03 trading range, but the out-of-the-money warrants ($0.05) limit immediate upside dilution pressure.
  • This does not alter the fundamental risk profile; it merely extends the timeline to the next inevitable capital raise.
RVV · Price
Company Overview
  • Revive Therapeutics is a clinical-stage biotechnology company focused on drug repurposing and medical countermeasures.
  • Core asset: Bucillamine, a thiol-based drug with over 30 years of clinical history in Japan and South Korea for rheumatoid arthritis.
  • Strategic pivot: Expanding bucillamine into infectious diseases, nerve-agent exposure, chemical threats, and long COVID.
  • Secondary pipeline: Psilocybin therapeutics, currently paused pending financing.
  • Business model: Relies on intellectual property expansion, government partnerships (e.g., DRDC), and potential licensing or procurement contracts rather than direct commercial sales.
Read the original news release →

More from Revive Therapeutics Ltd.

May 20, 2026 · 07:45

Revive Therapeutics Patents Fuel Defense Strategy Amidst Price Consolidation

M&A / Property Mar 11, 2026 · 17:34

Revive Therapeutics advances bucillamine patents

M&A / Property Mar 11, 2026 · 07:30

Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases

M&A / Property Dec 15, 2025 · 17:09

Revive Therapeutics primes the pump on Bucillamine

Other Dec 15, 2025 · 07:30

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

Other Nov 21, 2025 · 16:56

Revive talks DRDC study on bucillamine for nerve agents

Other